Identification and characterization of related substances in pomalidomide by hyphenated LC–MS techniques
Authors:
- 1 October 2015
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 114, 159-167
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analysesJournal of Pharmaceutical and Biomedical Analysis, 2014
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014
- Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueJournal of Pharmaceutical and Biomedical Analysis, 2014
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administrationCancer Chemotherapy and Pharmacology, 2012
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia, 2010
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1Blood, 2006
- Supramolecular Oxidation of Anilines Using Hydrogen Peroxide as Stoichiometric OxidantJournal of the American Chemical Society, 2005
- Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 2003
- Development of validated stability-indicating assay methods—critical reviewJournal of Pharmaceutical and Biomedical Analysis, 2002